Fresenius Kabi – Oncology & Critical Care Medicines
Fresenius Kabi
Fresenius Kabi is a German healthcare company within the Fresenius SE & Co. KGaA group, headquartered in Bad Homburg, Hesse. The parent company's shares are listed on the Frankfurt Stock Exchange. Fresenius Kabi took its present form in 1999, when Fresenius merged its pharmaceutical business with the international clinical nutrition business it had bought from Pharmacia & Upjohn.
The company specialises in medicines and technologies for infusion, transfusion and clinical nutrition. Its portfolio includes generic intravenous drugs (including for oncology, anaesthesia and intensive care), infusion solutions, parenteral and enteral nutrition, and medical devices such as infusion pumps, blood transfusion systems and disposables.
Fresenius Kabi also develops biosimilars for autoimmune diseases and cancer: in 2017 it bought the biosimilars business of Merck KGaA, and in 2022 it acquired a majority stake in Spain's mAbxience.
In 2008 Fresenius Kabi bought a controlling stake in India's Dabur Pharma, which became the basis of its oncology business in India, and acquired APP Pharmaceuticals in the US.
Unifarm carries Indian-made Fresenius Kabi medicines: Thalix 50 and Thalix-100 (thalidomide), used in multiple myeloma.